AEterna Zentaris Inc. (AEZS)
| Market Cap | 75.48M |
| Revenue (ttm) | 3.65M |
| Net Income (ttm) | -5.12M |
| Shares Out | 121.30M |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 282,208 |
| Open | 0.610 |
| Previous Close | 0.611 |
| Day's Range | 0.605 - 0.622 |
| 52-Week Range | 0.290 - 3.620 |
| Beta | 2.22 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 4, 2021 |
About AEZS
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maxi...
Financial Performance
In 2020, AEZS's revenue was $3.65 million, an increase of 586.47% compared to the previous year's $532,000. Losses were -$5.12 million, -15.29% less than in 2019.
Financial StatementsNews
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified ...
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a P...
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for the ...
Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis
Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational new drug...
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a d...
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets
Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientif...
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology
Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...
3 Penny Stocks to Watch During the Last Week of April
As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
– Company executing on growth strategy to build-out pipeline of development assets
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...
AEZS Stock: Why Aeterna Zentaris Shares Are Shooting Higher Today
Investors in AEZS stock have continued to pile into this trade today, with the stock up more than 40% on news around its Covid-19 vaccine. The post AEZS Stock: Why Aeterna Zentaris Shares Are Shooting H...
Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vacc...
Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-1...
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerz...
- Company secures next step to continue to build-out pipeline of assets
If You Like Long Shots, Aeterna Zentaris Stock Is Worth a Gamble
AEZS stock isn't something to bet your entire portfolio on, but since the company's a Covid-19 vaccine contender, it might be worth owning. The post If You Like Long Shots, Aeterna Zentaris Stock Is Wor...
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program fo...
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will ...
Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics an...
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares
CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing th...
Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing th...